Health Economics›Ewing sarcoma pediatric›Upfront therapy localized disease

Upfront therapy localized disease

Ewing sarcoma pediatric · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
COG AEWS0031 Protocol A N/A - secondary systemic drug	—	R 48 679	21d	—	—	—	—	—
COG AEWS0031 Protocol B N/A - secondary systemic drug	—	R 48 679	14d	—	—	—	—	—

2 of 2 regimens shown